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Microenvironment and Immunology
NOS Inhibition Modulates Immune Polarization
and Improves Radiation-Induced Tumor Growth
Delay
Lisa A. Ridnour1, Robert Y.S. Cheng1, Jonathan M.Weiss2, Sukhbir Kaur3,
David R. Soto-Pantoja3, Debashree Basudhar1, Julie L. Heinecke1, C. Andrew Stewart2,
William DeGraff1, Anastasia L. Sowers1, Angela Thetford1, Aparna H. Kesarwala4,
David D. Roberts3, Howard A.Young2, James B. Mitchell1, Giorgio Trinchieri2,
Robert H.Wiltrout2, and David A.Wink1
Abstract
Nitric oxide synthases (NOS) are important mediators of
progrowth signaling in tumor cells, as they regulate angio-
genesis, immune response, and immune-mediated wound
healing. Ionizing radiation (IR) is also an immune modulator
and inducer of wound response. We hypothesized that radi-
ation therapeutic efficacy could be improved by targeting
NOS following tumor irradiation. Herein, we show enhanced
radiation-induced (10 Gy) tumor growth delay in a syngeneic
model (C3H) but not immunosuppressed (Nu/Nu) squa-
mous cell carcinoma tumor-bearing mice treated post-IR
with the constitutive NOS inhibitor NG-nitro-L-arginine meth-
yl ester (L-NAME). These results suggest a requirement of
T cells for improved radiation tumor response. In support
of this observation, tumor irradiation induced a rapid increase
in the immunosuppressive Th2 cytokine IL10, which was
abated by post-IR administration of L-NAME. In vivo suppres-
sion of IL10 using an antisense IL10 morpholino also extend-
ed the tumor growth delay induced by radiation in a manner
similar to L-NAME. Further examination of this mechanism
in cultured Jurkat T cells revealed L-NAME suppression of
IR-induced IL10 expression, which reaccumulated in the pres-
ence of exogenous NO donor. In addition to L-NAME, the
guanylyl cyclase inhibitors ODQ and thrombospondin-1 also
abated IR-induced IL10 expression in Jurkat T cells and
ANA-1 macrophages, which further suggests that the immu-
nosuppressive effects involve eNOS. Moreover, cytotoxic Th1
cytokines, including IL2, IL12p40, and IFNg , as well as acti-
vated CD8þ T cells were elevated in tumors receiving post-IR
L-NAME. Together, these results suggest that post-IR NOS
inhibition improves radiation tumor response via Th1
immune polarization within the tumor microenvironment.
Cancer Res; 75(14); 2788–99. 2015 AACR.
Introduction
Radiotherapy remains a primary mode of treatment for more
than 50% of cancer patients in North America (1). At the molec-
ular level, ionizing radiation (IR) exerts its antitumor effects by
inducing direct DNA damage in the form of DNA double-strand
breaks as well as indirect damage by the generation of reactive
oxygen species (2). Although DNA damage has a central role in
radiation-induced tumor cell death, it does not fully account for
tumor response to local radiation. In addition to stimulation of
DNA repair, IR induces multiple cellular signaling pathways.
Importantly, cell survival depends upon the ratio of activated
pro- and antiproliferative pathways, suggesting that irradiated
cells, which evade death, survive and progress to more aggressive
and therapeutically resistant tumors (3). Radiation-induced
signaling pathways associated with cancer progression include
elevated epidermal growth factor receptor, hypoxia inducible
factor-1 (HIF1), upregulation, and/or activation of matrix metal-
loproteinases (MMP), and overexpression of cytokines, including
vascular endothelial growth factor (VEGF) and other immuno-
suppressive mediators that promote cancer survival, invasion,
and metastasis (4). Thus, the biology of sublethally irradiated
tumor cells favor survival, invasion, and angiogenesis, suggesting
that therapeutic efficacy could be improved by combining radi-
ation treatment with agents that target these or other progrowth
pathways induced by radiation (5).
Nitric oxide (NO) is an important mediator of many pro-
growth signaling cascades in cancer (6–9). Nitric oxide
synthases (NOS) catalyze the production of NO by the five-
electron oxidation of a guanidino nitrogen atom of the sub-
strate L-arginine, which requires NADPH, FAD, FMN, heme,
and O2 as cofactors (10). Three NOS isoforms are known to
exist; neuronal NOS (nNOS or NOS1), inducible NOS (iNOS
or NOS2), and endothelial NOS (eNOS or NOS3). NO has
many diverse roles in normal physiology and tumor biology,
which are spatially, temporally, and concentration dependent.
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The constitutive isoforms eNOS and nNOS are tightly regulated
by Ca2þ/calmodulin, and produce low flux (pmol/L) NO over
short periods of time. In contrast, the inducible isoform iNOS is
Ca2þ independent and generates higher flux NO over a longer
period of time that can range from nmol/L to mmol/L in
concentration, depending upon the stimulant (11). NOS has
been studied extensively in carcinogenesis. Although elevated
NOS3 expression has a role in tumor angiogenesis, increased
NOS2 expression predicts poor therapeutic response, tumor
progression, and decreased patient survival (9, 12–15). To date,
our molecular signatures suggest that NO-mediated prosurvi-
val, cell migration, angiogenesis, and stem cell marker (i.e.,
ERK, Akt, IL8, IL6, S100A8, CD44) signaling in tumors and
tumor cells occurs at 400 nmol/L steady-state NO (6, 9).
Together, these observations suggest that the NOS enzymes are
exploitable therapeutic targets.
NO produced by the constitutive eNOS isoform controls
blood flow and is a key mediator of the pro-angiogenic effects
of vascular endothelial growth factor (VEGF; ref. 16). A clinical
study demonstrated reduced tumor blood volume within 1 hour
of administration of the competitive NOS inhibitor nitro-L-
arginine (L-NNA), which lasted for 24 hours in all patients
studied (17). Side effects of NOS inhibition included bradycar-
dia and hypertension, which were not study limiting and suggest
that NOS inhibition may be a beneficial therapeutic option for
combined modalities (17). Advances in radiotherapy have
included the co-administration of anti-angiogenic (AA) drugs,
which radiosensitize endothelial cells (18). IR also activates
constitutive NOS, as well as ERK1/2 kinase prosurvival signal-
ing, both of which were blocked by L-NNA (19). In addition,
the administration of L-NNA 24 hours prior to 10 Gy irradi-
ation of tumor-bearing mice demonstrated reduced tumor
blood flow and increased tumor cell apoptosis when compared
to mice receiving radiation or L-NNA alone, further supporting
NOS inhibition as a target to improve radiation therapeutic
response (20).
In addition to targeting tumor vasculature, IR modulates host
immunity and mimics vaccine response by enhancing the
release of damage-associated molecular patterns (DAMP) from
dying cells, which then activate cytotoxic lymphocytes (CTL)
through toll-like receptor activation (21). IR facilitates antigen-
presenting cell and T-cell penetration into the tumor (22), and
also impacts host immunity through modulation of both pro-
and antitumor responses depending upon the Th1 (cytotoxic)
versus Th2 (immunosuppressive) cytokine milieu and associ-
ated immune cell mediators (21). Macrophages exposed to
Th1 cytokines exhibit increased levels of pro-inflammatory
cytokine production, antigen presentation, and cytotoxic activ-
ity. In contrast, macrophages exposed to Th2 cytokines exhibit
an immunosuppressive phenotype associated with blocked
CTL activity, increased angiogenesis, tissue restoration, and
wound healing response (23). T-regulatory cells (Tregs) are
pivotal mediators of immune suppression and the develop-
ment of immunologic tolerance through their ability to limit
antitumor immune responses (24). Tregs mediate tumor
immune tolerance in part through the secretion of IL10, TGFb,
or IL35 immunosuppressive molecules (24). Indeed, IL10 and
TGFb derived from Tregs promote tumor progression through
antitumor immune suppression (25). NO also mediates both
cGMP-dependent and -independent Th1–Th2 immune transi-
tion and may be important in the tumor response to radiation-
induced injury (26, 27). To explore this hypothesis, we exam-
ined cytokine expression profiles and T-cell activation during
radiation-induced tumor growth delay in a syngeneic model




Jurkat cells (Jurkat clone E6-1) were obtained from the ATCC
and maintained in 5% CO2, RPMI-1640 culture medium with
10% FBS and 100 IU/mL Pen Strep antibiotics (Life Techno-
logies). Jurkat cells were treated with IR (0, 1, or 5 Gy) in the
presence or absence of various concentrations of DETA/NO
(0, 30, 60, 100, 300, 500, and 100 mmol/L), L-NAME (0, 500,
or 1,000 mmol/L), or the guanylyl cyclase inhibitor ODQ (10
mmol/L) or thrombospondin-1 (TSP-1: 1 mg/mL). The NONOate
donors, includingDETA/NO, are stable whenmaintained in basic
conditions (10 mmol/L NaOH) but release NO at defined rates
at physiologic pH (28); 10 mmol/L NaOH served as vehicle
control in experiments utilizing the NO donor DETA/NO.
The ANA-1 macrophage cell line used in this study was establish-
ed by immortalization of bone marrow macrophages from
C57BL/6 mice with J2 recombinant retrovirus-expressing
v-myc/v-raf oncogenes (29). ANA-1 cells were grown in DMEM
supplemented with 10% FBS and 1% penicillin–streptomycin,
plated at a density of 5 105 perwell in a 12-well plate and grown
overnight.
Suppression of IL10
Silencing of IL10 protein translation was accomplished by
using an antisense 25-mer oligo (Gene Tools) designed specifi-
cally to block the AUG translational start site of mouse IL10
(GenBank accession no. NM_010548: oligo sequence, 5-
AGCTCTCTTTTCTGCAAGGCTGCTT). This oligo complements
the sequence from 31 to 6 relative to the initiation codon.
Suppression of secreted IL10 protein levels were verified in lipo-
polysaccharide (LPS)-stimulated Raw 267.4 (30) cells pretreated
with control or IL10morpholino.Cell culturemediawas collected
at 24 and 48 hours and IL10 protein levels were measured by
ELISA assay (R&D Systems) according to the manufacturer's
recommendations.
In vivo mouse tumor model
The Animal Care and Use Committee (National Cancer
Institute, NIH, Bethesda, MD) approved mouse protocols.
Female C3H/Hen or athymic nude mice were supplied by the
Frederick Cancer Research and Development Center Animal
Production Area (Frederick, MD). The animals were received
at 6 weeks of age, housed five per cage, and given autoclaved
food and water ad libitum. Experiments were performed at 9 to
10 weeks of age and in accordance with principles outlined in
the Guide for the Care and Use of Laboratory Animals (Institute of
Laboratory Animal Resources, National Research Council,
Washington, DC). Squamous cell carcinoma VII/SF tumor cells
(SCC) were derived from spontaneous abdominal wall squa-
mous cell cancer (obtained from Dr. T. Phillips, UCSF, San
Francisco, CA) and propagated in C3H/Hen mice (31). For
growth delay studies, 2  105 viable SCC cells were injected into
the subcutaneous space of the right hind leg of 8-week-old
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C3H/Hen or nude mice and grown for 1 week when tumor size
reached approximately 200 mm3 in size. Similarly, human
colon carcinoma HT29 tumor xenografts were grown in nude
mice injected with 1  106 cells. C57BL/6 WT or eNOS/ (The
Jackson Laboratory Stock No. 002684) mice on the same
background were injected with 1  106 B16 melanoma cells.
SNP analysis (DartMouse, The Geisel School of Medicine at
Dartmouth, Dartmouth, NH) demonstrated background puri-
ties of C57BL/6 WT and eNOS/ mice to be 99.8% and 98.9%,
respectively, when compared to the in-house control. Tumor
volume was measured by caliper and calculated as mm3 ¼
[width2  length]/2 where width was the smaller dimension.
Tumor irradiation was accomplished by securing each animal in
a specially designed Lucite jig fitted with lead shielding that
protected the body from radiation while allowing exposure of
the tumor-bearing leg. A Therapax DXT300 X-ray irradiator
(Pantak, Inc.) using 2.0 mm A1 filtration (300 KVp) at a dose
rate of 2.53 Gy/min was used as the X-ray source. Irradiated
tumors received one 10 Gy dose. Designated groups of animals
were treated with NOS inhibitor L-NAME or IL10 suppressing
agents. NOS inhibition was achieved by administering L-NAME
post-IR in the drinking water at a concentration of 0.5 g/L for
the duration of the experiment (20). IL10 protein levels were
suppressed using an IL10 morpholino; mice were injected with
a 750 mL volume of 10 mmol/L IL10 morpholino (Gene Tools)
or a four base-mismatched control morpholino in saline 48
hours prior to irradiation. After irradiation, the mice were
returned to their cages, and tumors were measured three times
each week thereafter to assess tumor growth. Animals were
euthanized when tumor growth approached the maximum
allowable limit.
Cytokine screen
Control and irradiated tumors (L-NAME) were collected at 0,
0.25, 1, 2, 3, 4, and 7 days post-irradiation. Cytokine protein
expression was evaluated by Q-Plex multiplex ELISA arrays
(QUANSYS Biosciences).
Isolation of leukocytes from spleen
Spleens were harvested from tumor-bearing animals, placed in
sterile saline, and filtered through a two-chamber sterile Filtra-Bag
(Fisher Scientific). Splenocytes were counted by Sysmex KX-21
(Roche Diagnostics).
Isolation of tumor-infiltrating leukocytes
Tumors were dissected and filtered through a two-chamber
sterile Filtra-Bag (Fisher Scientific), then digested in RPMI
containing 5% fetal calf serum, 700 units/mL collagenase (Invi-
trogen), 100 mg/mL DNAse I (Boehringer Mannheim), and 1
mmol/L EDTA (pH8.0), at 37C for 45minutes. The homogenate
was then processed in a tissue stomacher-80 (Seward) for 30
seconds, washed with HBSS (BioWhittaker), and resuspended in
40% Percoll (Amersham Pharmacia) in DMEM medium (Bio-
Whittaker). The suspension was underlaid with 80% Percoll and
centrifuged for 25minutes at 1,000 g. Leukocytes were collected
from the interphase, washed, and counted.
Flow cytometry
Cells (1  106) were incubated in cell staining buffer (0.1%
BSA, 0.1% sodium azide) containing 250 mg/mL 2.4G2 ascites,
which blocks nonspecific Fc receptor antibody binding for 15
minutes. Cells were stained with fluorescently conjugated anti-
bodies (BD Pharmingen) for 20 minutes. Labeled cells were
washed twice in cell staining buffer and analyzed on a BD Facs
Canto II flow cytometer (Becton Dickinson).
RNA extraction, reverse transcription, and quantitative real-
time PCR
Total RNA was extracted with TRizol (Invitrogen) according
to the manufacturer's protocol. RNA samples were reverse
transcribed into cDNA using Sprint RT Complete 8-well strips
(Clontech) according to the manufacturer's recommendation.
Primer pairs were designed for IL10 that recognized F:
TTAAGGGTTACCTGGGTTGC and R: GCCTGAGGGTCTT-
CAGGTTC sequences using the IL10 gene Ref Seq sequences by
Primer3 (32). All quantitative real-time PCR reactions were
designed to follow a universal real time PCR condition: 94C 2
minutes, 45 cycles of 94C 30 seconds, and 60C 30 seconds in
PowerSYBR Master Mix (Applied Biosystems). Amplicon speci-
ficity was checked by BLAST search and on a 2% FlashGel (Lonza)
to ensure that neither nonspecific amplicons nor primer–dimer
complexes were formed. Relative expression was calculated using
the ddCt formula. Amplification efficiencies for primers were
checked against the 18S housekeeping gene to ensure signals
were detected in PCR exponential phase and that primers had
similar amplification efficiencies.
Jurkat and CD47-deficient JinB8 Jurkat cells (1 106; ref. 33)
were plated on 12-well plates (Corning) using RPM1 medium þ
2% FBS at 37C in 5% CO2 and treated with 1 mg/mL TSP-1 for
6 hours. Untreated cells were used as controls. Total RNA was
extracted using TriPure Isolation Reagent (Roche). The first
strand cDNA was made using Maxima First Strand cDNA
Synthesis Kit for RT-qPCR (Thermo Scientific). Primer
sequences for hypoxanthine phosphoribosyltransferase 1
(HPRT1; 50-ATT GTA ATG ACC AGT CAA CAG GG-30/50-GCA
TTG TTT TGC CAG TGT CAA-30) and IL10 (50-AAA TTA GCC
GGG CAT GGT GG-30/50-CTG CAA CTT CCA TCT CCT GGG T-
30) were used for real-time PCR performed using SYBR Green
(Roche) on an MJ Research Opticon I instrument (Bio-Rad)
with the following amplification program: 95C for 15 min-
utes, followed by 40 cycles of 95C for 15 seconds, 58C for 20
seconds, 72C for 25 seconds, and 72C for 1 minute. Melting
curves were performed for each product from 30C to 95C,
reading every 0.5C with a 6-second dwell time. Fold change in
mRNA expression was calculated by normalizing to HPRT1
mRNA level. Two-factor ANOVA with replication was used for
statistics analysis.
Automated capillary Western blot
Western blots were performed using WES, an automated
capillary-based size sorting system (ProteinSimple; ref. 34). All
procedures were performed with manufacturer's reagents
according to their user manual. Briefly, 8 mL of diluted protein
lysate was mixed with 2 mL of 5 fluorescent master mix and
heated at 95C for 5 minutes. The samples (1 mg), blocking
reagent, wash buffer, primary antibodies, secondary antibodies,
and chemiluminescent substrate were dispensed into designat-
ed wells in a manufacturer provided microplate. The plate
was loaded into the instrument and protein was drawn into
individual capillaries on a 25 capillary cassette provided by
the manufacturer. Protein separation and immunodetection
was performed automatically on the individual capillaries
Ridnour et al.
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using default settings. The data were analyzed using Compass
software (ProteinSimple; ref. 34). Primary antibodies used
were nNOS, eNOS (Cell Signaling), and iNOS (Santa Cruz
Biotech) HPRT was used as loading control (Santa Cruz
Biotech).
Statistical analysis
All results are expressed as the mean  SEM. The differences in
means of groups were determined by the Student t test with the
minimum level of significance set at P  0.05.
Results
NOS inhibition enhances radiation-induced tumor growth
delay in syngeneic mice
Tumor growth delay is described by the substance enhance-
ment ratio (SER), which is the ratio of time required for treated
versus control tumors to reach a defined size (1,000 mm3). The
effect of NOS inhibition by L-NAME, a NOS inhibitor that is
more selective for the constitutive isoforms (eNOS and nNOS;
ref. 35), on radiation-induced tumor growth delay was examined
in a syngeneic murine model of SCC tumor-bearing C3H mice.
L-NAMEwas administered in the animals' drinkingwater (0.5 g/L)
following tumor irradiation (post-IR, 10 Gy). Because NO reg-
ulates vascular tonicity, we chose post-IR administration
of L-NAME to minimize vascular constriction and maintain
tumor pO2 prior to and during tumor irradiation while targeting
vascular constriction post-IR. Figure 1A demonstrates enhanced
radiation-induced tumor growth delay in mice that received
post-IR L-NAME (SER 3.3) when compared to tumors treated
with 10 Gy IR alone (SER 1.8). The iNOS-specific inhibitor
aminoguanidine was also tested, and yielded an SER of 2.1.
Interestingly, L-NAME–mediated NOS inhibition had no effect
on the radiation-induced tumor growth delay of HT29 human
adenocarcinoma cells or SCC xenografts in immunosuppressed
nude mice lacking T cells (Fig. 1B and C, respectively). These
results indicate a requirement of T cells for L-NAME potentiation
































































10 Gy + L-NAME
10 Gy + AG
* P = 0.048  day 14
** P = 0.01    day 16
**
*
10 Gy + L-NAME vs. 10 Gy + AG  P value
Figure 1.
Radiation-induced tumor growth delay is
enhanced by post-IR administration of L-NAME
and requires cytolytic T cells in SCC tumor
xenografts grown in female syngeneic C3H/Hen
mice. Post-IR aminoguanidine, a selective iNOS
inhibitor, was less effective than L-NAME at
extending radiation-induced tumor growth
delay (A). Human HT29 colon carcinoma (B) and
SCC (C) xenografts grown in female athymic
nude mice showed no effect of post-IR L-NAME
on radiation-induced tumor growth delay. Mice
were injected with 2  105 SCC (A and C) or
1  106 HT29 (B) tumor cells in the right hind
leg and grown for 1 week to allow formation of
palpable tumors of uniform size (200 mm3).
On day 7, animals received tumor
irradiation  post-IR L-NAME (or
aminoguanidine) in the animals drinking
water (0.5 g/L). Data, mean  SEM; n  5
animals per group.
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Effect of L-NAME on radiation-induced cytokine expression
in syngeneic mice
T cells are lymphocytes that direct cell-mediated immunity
and are distinguished from other lymphocytes by the presence
of cell surface T-cell receptors. There are several subsets of
T cells, each with a distinct function; proliferating helper T
cells differentiate into two major types of effector T cells known
as Th1 and Th2 cells, which secrete specific cytokines that
mediate different immune responses. Th1 cells are proinflam-
matory, mediate host immunity to foreign pathogens, and are
induced by IL2, IL12, and their effector cytokine IFNg (36).
In contrast, Th2 cells are immunosuppressive, secrete IL4, IL5,
IL10 as well as TGFb, and mediate wound resolution following
pro-inflammatory assault (37). To explore a potential role for
NOS-derived NO during radiation-induced T-cell response,
QPlex was used to examine alterations in tumor cytokine
expression. Supplementary Table S1 summarizes the impact
of NOS inhibition by L-NAME, on the trend of Th1 versus Th2
cytokine protein expression induced by 10 Gy tumor irradia-
tion, whereas Supplementary Table S2 summarizes pg/mg cyto-
kine levels as well as P-values and fold-change, as a function of
time after irradiation. The trend of Th1 versus Th2 cytokine
protein expression summarized in Supplementary Table S1
suggests that tumors receiving radiation alone rapidly acquire
(within 24 hours) an overall Th2 signaling profile as defined by
early elevation of IL10 (Day 1) followed by increased IL5, IL3,
and IL4 tumor expression (Day 2–4). In contrast, tumors from
animals that received post-IR L-NAME exhibited a Th1 profile as
defined by elevated IL2 (6 hours, Day 1), IL12, and IFNg (Day 3,
4, 7) tumor expression. The most profound observation per-
tained to the dramatic early induction of IL10 24-hour post-IR,
which was abated by L-NAME (Fig. 2A). These results suggest
the rapid induction of an IL10-mediated immunosuppressive
phenotype in response to tumor irradiation, which was abol-
ished by post-IR NOS inhibition. We also examined tumor
NOS isoform protein expression 24-hour post-IR. When com-
pared to control, Fig. 2B shows increased iNOS protein expres-
sion in the 10 and 10 Gy þ L-NAME tumors. This is an
interesting observation considering that constitutive NOS
inhibition by L-NAME was more effective in extending the
radiation-induced tumor growth delay. This may be explained
by the findings of Connelly and colleagues (38) who demon-
strated that eNOS is required for the full activation of iNOS.
NO–induced IL10 expression in Jurkat T cells and ANA-1
macrophages
IL10 is generally produced by differentiated monocytes and
lymphocytes (i.e., macrophages and T cells, respectively). To
further examine the involvement of NO during radiation-
induced IL10 expression, we used Jurkat cells, which are T
lymphocytes that express IL10 and are commonly employed
to study T-cell signaling. Cytokine expression profiles were
examined in cells exposed to the slow releasing NO donor
DETA/NO, which mimics NO flux under inflammatory condi-
tions. Figure 3 demonstrates NO concentration-dependent
induction of IL10 mRNA (A) and protein (B) in Jurkat cells,
which peaked at 300 mmol/L DETA/NO. Next, Jurkat cells were
exposed to 1 Gy irradiation, then treated with or without
L-NAME, and incubated overnight to mimic the tumor xeno-
graft irradiation protocol. Figure 3C shows a greater than four-
fold increase in Jurkat IL10 expression 24 hours after 1 Gy
irradiation, which was abated by L-NAME and is similar to the
L-NAME effect on radiation-induced tumor IL10 expression
shown in Fig. 2. Interestingly, the L-NAME suppressed IL10
levels re-accumulated to that induced by 1 Gy irradiation in the
presence of the exogenous NO donor DETA/NO at concentra-
tions of 100 to 500 mmol/L or 400 nmol/L steady-state NO
(Fig. 3C; refs. 6, 7, and 12). To date, our breast cancer bio-
marker signatures suggest that NO-mediated prosurvival, cell
migration, angiogenesis, and stem cell marker (i.e., ERK, Akt,
IL8, IL6, S100A8, CD44) signaling in tumors and tumor cells
occurs at 400 nmol/L steady-state NO (6, 7, 9, 12, 39). When
considering this molecular signature, the results shown in Fig.
3A–C are consistent with our earlier reports and suggest that
400 nmol/L steady-state NO modulates radiation-induced
IL10 expression in Jurkat cells. Also, the NO flux-dependent
regulatory trend of IL10 shown in Fig. 3C resembles a bell-
shaped curve, which is consistent with low flux NO regulation
of wound response vs. high flux NO-mediated toxicity (11,
40–42).
L-NAME is more selective for the constitutive NOS isoforms,
which implicates possible eNOS/cGMP-dependent signaling
(35, 43). To explore the potential of cGMP-dependent signaling
during radiation-induced IL10 expression, Jurkat cells were
exposed to 1 Gy IR  the guanylyl cyclase inhibitor ODQ, which
completely abolished IL10 expression induced by 1 Gy IR (Fig.
3D). TSP-1 inhibits NO signaling through its receptor CD47 by
inhibiting eNOS activation and abating NO-dependent cGMP
synthesis and cGMP-dependent protein kinase signaling in vas-
cular cells and Jurkat T cells (41, 42). Exogenous TSP-1 also
blocked radiation-induced Jurkat IL10 expression, suggesting
eNOS/cGMP-dependence for this process (Fig. 3D). Inhibition



























Control           10 Gy      10 Gy + L-NAME
Figure 2.
Radiation-induced tumor IL10 protein expression is abolished by post-IR
L-NAME. Data plotted as mean  SEM of two tumor lysate samples, each
measured in triplicate (A). B, NOS isoformprotein expression in control, 10Gy,
and 10 Gy þ L-NAME tumors 24 hours following tumor irradiation.
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IL10 mRNA (A) and protein (B) is induced in Jurkat T cells following overnight exposure to the NO donor DETA/NO. C, post-IR (24 hours), NOS inhibition by L-NAME
suppressed IL10 expression induced by 1 Gy radiation of Jurkat T cells, which rebounded in the presence of DETA/NO. D, post-IR (24 hours), L-NAME treatment
as well as guanylyl cyclase inhibition by guanylyl cyclase inhibitors ODQ or TSP-1 also suppressed IL10 expression induced by 1 Gy radiation in Jurkat T cells. E, TSP-1
treatment for 6 hours decreased IL10 mRNA expression in WT but not CD47-deficient Jurkat cells. F, radiation-induced IL10 expression is suppressed in ANA-1
macrophages treated post-IR with L-NAME, ODQ, or TSP-1. G and H, Jurkat cell viability in response to DETA/NO (G) or 1 Gy IR (H). Data, mean  SEM of n  3 per
treatment group.
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inhibition of basal IL10 mRNA expression was lost in the CD47-
deficient Jurkat mutant JinB8 (Fig. 3E). The 2-fold stimulation
of IL10 mRNA by TSP-1 in the CD47 mutant is consistent with
reported positive effects of TSP-1 on IL10 expression mediated
by the TSP-1 receptor CD36 (44). Radiation also induced IL10
in murine ANA-1 macrophages, which was abated by L-NAME,
ODQ and TSP-1, indicating that cGMP-dependent regulation
of IL10 is not restricted to T cells (Fig. 3F). Collectively, these
results indicate that radiation-induced IL10 expression in T cells is
tightly controlled by low constitutive NOS-derived NO flux.
IL10 suppression enhances radiation-induced tumor growth
delay
Post-IR NOS inhibition by L-NAME enhanced radiation-
induced tumor growth delay and abated radiation-induced IL10
expression (Figs. 1A and 2, respectively). To examine a role of IL10
in the recovery from post-IR tumor growth delay, IL10 protein
translation was suppressed by treatment with an IL10 morpho-
lino (45, 46). Confirmation of the morpholino efficacy for IL10
protein suppression was verified using LPS-stimulated Raw 267.4
cells because LPS is a strong inducer of IL10 in these cells (30) as
shown in Fig. 4A. Next, tumor-bearing animals were treated with
IL10 or control morpholino 48 hours prior to tumor irradiation.
IL10 morpholino treatment enhanced the radiation-induced
tumor growth delay (SER 2.7) as shown in Fig. 4B in a manner
similar to that observed by L-NAME (Fig. 1A) but had no effect on
tumor growth in the absence of radiation. These results suggest
that radiation-induced tumor growth delay can be improved by
inhibiting IL10-mediated immunosuppressive signaling in the
C3H/SCC syngeneic model.
L-NAME increases tumor-associated CD8þ cytolytic T cells
post-IR
Cytotoxic T lymphocytes are a subgroup of T cells that when
activated kill invading pathogens and tumor cells. These cells are
commonly referred to as CD8þ T cells because they express cell
surface CD8 glycoprotein. Importantly, immunosuppressive
molecules, including IL10, can inactivateCD8þ T cells. To identify
the presence of CD8þ T cells, markers of tumor lymphocyte
infiltration were examined in control and 10 Gy  L-NAME
tumors, as well as spleen from tumor-bearing mice. Figure 5A
shows increased tumor-associated CD8þ T cells in irradiated
tumors treated with L-NAME but not spleen taken from the same
animals (Fig. 5B). CD69 is amarker of T-cell activation. Figure 5C
demonstrates increased CD8þ CD69þ mean fluorescence inten-
sity in infiltrating lymphocytes from irradiated tumors treated
with L-NAME but not in spleen taken from the same animals (Fig.
5D). Importantly, these results implicate a localized tumor
response culminating in the elevation of activated cytotoxic T
cells in post-IR NOS inhibited tumors. Neutrophils, dendritic
cells, and immature myeloid cells from post-IR treated L-NAME
tumors were elevated on day 3, when compared to irradiated
tumors (Fig. 5E–G). In contrast, Tregs and natural killer cells did
not change (Fig. 5H and I). Collectively, these results demonstrate
that altered NO flux via L-NAME–mediated NOS inhibition can
improve the efficacy of therapeutic radiation by immune polar-
ization favoring a proinflammatory phenotype within the tumor
microenvironment in an SCC/C3H syngeneic model.
L-NAME is more selective for inhibiting the constitutive
NOS isoforms (eNOS and nNOS) and our cell culture results
implicate eNOS/cGMP-dependent signaling (Fig. 3) in the
immune polarization shown in Fig. 5. To further explore a role
of eNOS in the potentiation of radiation therapeutic efficacy, we
examined the radiation-induced tumor growth delay of murine
B16 melanoma xenografts in wild-type (WT) and eNOS knock-
out (eNOS/) mice on the C57BL/6 background (Fig. 6A).
When compared to control, the irradiated tumor in WT mice
yielded an SER of 2 (Fig. 6A), which is consistent with the
SCC/C3H syngeneic model shown in Fig. 1A. Remarkably, the
irradiated tumor in eNOS/ animals exhibited an SER of 5.5
when compared to the WT-irradiated tumor (Fig. 6A). Interest-
ingly, IL10 protein was not detected in B16 xenografts grown in
WT C57BL/6 or eNOS/ on the same background under these
conditions; however, the cytokine protein expression profile of
irradiated tumors in eNOS/ mice exhibited significantly ele-
vated Th1 cytokines, including IL2, TNFa, and IFNg , as shown
in Fig. 6B–D. Importantly, radiation has been shown to induce
eNOS expression, which promotes tumor recovery from radiation
injury (47). Together, these results suggest that eNOS has a vital
role in acute tumor radiation response and that improved phar-
macology of NOS inhibitors in combination with radiation may
be therapeutically beneficial.
Discussion
The role of NO flux within the tumor microenvironment
as it relates to therapeutic efficacy is complex. Studies have
shown that steady-state NO modulation within the tumor
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A, LPS is a strong inducer of IL10 protein in Raw 267.4 cells, which is abated
by IL10 morpholino (IL10 M). B, IL10 morpholino was administered
intraperitoneally to SCC tumor-bearing C3H mice 48 hours prior to tumor
irradiation. IL10 suppression by IL10 morpholino enhanced radiation-induced
tumor growth delay of SCC xenografts. Data, mean  SEM of 5 animals per
group.
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Post-IR NOS inhibition by L-NAME increased percentage of CD8þ T cells and activation measured by CD8 CD69 MFI in tumors (A and C) but not spleen
(B and D) in SCC xenografts. Elevations in the percentage of tumor neutrophils, dendritic cells, and immature myeloid cells were also observed on day
3 in post-IRþL-NAME tumors, when compared to tumors receiving 10 Gy radiation alone (E–G). Cell surface marker expression was measured by
flow cytometry 2 to 4 days (A–G) or 24 hours (H and I) post-IR in SCC xenografts.
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efficacy (20, 47, 48). NO mediates numerous effects at the
cellular and physiological levels. Similar to molecular O2, the
outer p orbital of NO has an unpaired electron, which imparts a
high affinity for other radicals, including radiation-induced
carbon radicals on DNA, which leads to fixed DNA damage
and enhanced NO-mediated radiosensitivity (49). In support
of this early observation, a recent study demonstrated that
the presence of low steady-state NO dramatically enhanced
radiosensitization as well as increased the time of DNA repair,
when compared to anoxic and aerated control tumors (50).
Similarly, site-specific iNOS transgene expression driven by the
radiation-inducible pE9 promoter demonstrated enhanced
tumor radiation response under hypoxic conditions (51).
In addition to these direct effects of NO-mediated radiosensi-
tization, altered NO gradients prior to tumor irradiation have
been shown to normalize tumor vasculature, which increased
tumor oxygen tension and tumor response to radiation (52).
In contrast, administration of the NOS inhibitor L-NAME
before and after radiation minimized the cytotoxic effect of
NO under conditions of hypoxia (48). In this context, NO
improved radiation therapeutic efficacy by enhanced tumor
perfusion and oxygen effect (53). Thus, NO modulation prior
to and at the time of radiation is therapeutically beneficial.
Together, these studies demonstrate the contextual depend-
ence of timing and distinct mechanisms directed by NO flux
for improved tumor response to radiotherapy.
Although the modulation of tumor NO flux prior to irradi-
ation improves tumor oxygenation and radiation efficacy,
NO also promotes angiogenesis in the context of immune-
mediated wound response (40–42), which may facilitate post-
irradiation recovery of a sublethally irradiated tumor. Indeed,
macrophages employ NO generated by both eNOS and iNOS
during wound response (40, 54) and in vivo models have
shown delayed wound closure in iNOS knockout mice (55).
Toward this end, IR-induced angiogenesis (56) through NO
signaling (47), which promoted tumor recovery following
radiation injury. These observations suggest that post-irradia-
tion inhibition of angiogenesis may be beneficial. Thus, we
hypothesized that improved radiation therapeutic efficacy and
extended tumor growth delay may be achievable by targeting
NO flux through NOS inhibition following tumor irradiation.
Interestingly, post-IR administration of the constitutive NOS
inhibitor L-NAME extended radiation-induced tumor growth
delay and was more effective than the selective iNOS inhibitor
aminoguanidine (Fig. 1A). Moreover, L-NAME extended the
radiation-induced tumor growth delay only in syngeneic mice
but not nude mice. This observation implicates the involve-
ment of innate immunity and cytotoxic T cells in enhanced
radiosensitivity, which is regulated by NO flux, and further
supported by the cytokine expression profile of post-IR NOS-
inhibited tumors that expressed high levels of cytotoxic Th1
cytokines, including IL2, IFNg , and IL12p40, as summarized
in Fig. 7. In contrast, tumors receiving radiation alone exhibited
immunosuppressive Th2 signaling, as indicated by increased
IL10, IL5, and IL4 cytokine expression (Supplementary Tables
S1 and S2). Moreover, tumor cytokine expression analysis
revealed enhanced IL10 protein levels 24 hours following
tumor irradiation in SCC-tumor bearing C3H mice, which was
abolished by L-NAME (Fig. 2) and confirmed in irradiated
Jurkat T lymphocytes and ANA-1 macrophages (Fig. 3). Impor-
tantly, in vivo IL10 protein suppression extended radiation-
induced tumor growth delay in C3H mice in a manner similar
to that of L-NAME. These findings implicate a novel role for
NO as a stimulator of IL10-mediated tumor immunosuppres-
sive signaling, which accelerates tumor recovery and regrowth
in response to radiation injury in the C3H model.
Cytokine expression analysis of ANA-1 macrophages, and
Jurkat T cells demonstrated increased IL10 expression 24 hours
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A, radiation-induced tumor growth delay is enhanced in eNOS/ mice.
C57BL/6 WT or eNOS/ mice on C57BL/6 background were injected with
2  105 B16 tumor cells in the right hind leg and grown for 1 week to allow
formation of palpable tumors of uniform size (200mm3). On day 7, animals
received tumor irradiation. Data, mean SEM; n > 5 animals per group. B–D,
irradiated tumors fromeNOS/mice exhibited elevated protein levels of IL2,
TNFa, and IFNg proinflammatory Th1 cytokines.
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that radiation-induced IL10 could come from these cell types.
Although we used a variety of sensitive detection methods,
including flow cytometry analysis of IL10 associatedwithmarkers
of specific immune cell populations, as well as flow cytometry
analysis of GFP-IL10–taggedmice, we were unable to confirm the
specific cellular source of IL10 in our experiments. In addition, no
significant changes in Treg cell populations were observed that
might account for the cellular source of increased IL10 levels
following irradiation. Ongoing studies are aimed at identifying
the relative contributions of leukocyte subsets to IL10 following
tumor irradiation.
Flow cytometry analysis of immune cell mediators demon-
strated increased CD8þ expression and CD8þ/CD69þ MFI
(indicative of cytotoxic CD8þ T-cell activation) in post-
IR NOS-inhibited C3H tumor xenografts but not spleen
(Fig. 5A–D), implicating a localized immune response at the
irradiated tumor site. The results herein further support a
key role for NO flux-dependent regulation of IFNg and cyto-
toxic T-cell activation for improved radiation therapeutic
efficacy (Supplementary Tables S1 and S2; Figs. 5 and 6).
Indeed, cytotoxic CD8þ T cells mediate cell killing through
increased IFNg (57), and inhibition of either IFNg or CD8þ
T cells abolished the therapeutic efficacy of radiation in
colon adenocarcinoma tumor-bearing mice (58). In addition,
our results indicate that L-NAME potentiation of radiation
treatment efficacy is eNOS/cGMP-dependent. Suppression
of eNOS/cGMP-dependent signaling by the guanylyl cy-
clase inhibitors ODQ or TSP-1 abolished radiation-induced
IL10 expression in Jurkat T lymphocytes and ANA-1 macro-
phages (Fig. 3). Also, radiation-induced tumor growth delay
was dramatically enhanced in eNOS/ tumor xenografts,
which exhibited increased Th1 cytokine expression (Fig. 6).
Thus, radiation-induced tumor injury promotes a Th2 immu-
nosuppressive profile that is eNOS/cGMP-dependent and
involves low NO flux.
The post-IR NOS-inhibited tumor exhibited enhanced
expression of IL2, IFNg , and IL12p40 Th1 mediators (Supple-
mentary Table S1). IL2 is a pleiotropic cytokine that has pivotal
roles during immune regulation in response to foreign patho-
gens (59). IL2 is produced primarily by CD4þ T cells and
promotes the differentiation, expansion, and cytolytic activa-
tion of cytotoxic T cells. Importantly, IL2 effects are receptor
mediated; IL2 interaction with IL12Rb2 leads to upregulation
of IFNg and IL12 during Th1-cell differentiation (59). Interest-
ingly, a cGMP-dependent role of low flux NO in the selective
upregulation of IL12Rb2 has been reported (26). IL12 is also
important for sustaining memory/effector T cells, which pro-
mote long-term protection against pathogens and tumors. IL2
also interacts with IL2Ra to promote CD8þ T-cell differentia-
tion and activation (59). Importantly, these cytokine activation
CD8+ Active CD8+

















Post-IR NOS inhibition improves
tumor response to IR by increased Th1
immune polarization within the tumor
microenvironment.
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profiles are consistent with the time course analysis showing
elevated IL2, IFNg , and IL12p40 in the post-IR NOS-inhibited
tumors summarized in Supplementary Table S1, as well as
CD8þ T-cell regulation shown in Fig. 5. In contrast, tumors
receiving irradiation alone demonstrated increased IL10 fol-
lowed by elevated Th2 mediators IL5, IL3, and IL4. Interest-
ingly, IL2 was also elevated in these irradiated tumors and
may have played a role in the upregulation of IL4 and IL5 Th2
cell differentiation, which is IL4Ra dependent (59). The pro-
inflammatory cytokine IL1a was also observed in the irra-
diated tumor. Despite its proinflammatory status, IL1a released
by solid tumors acts as a chemoattractant to facilitate malig-
nancy-associated inflammatory responses (60).
Collectively, the results herein suggest a novel mechanism of
low flux NO during Th1–Th2 transition, tumor immunosuppres-
sive signaling, and accelerated wound recovery in the tumor
response to ionizing irradiation. Importantly, CD8þ T-cell regu-
lation and IFNg expression seem to be determined by NO flux-
dependent IL10 versus IL2 signaling cascades, which can be
modulated by pharmacological NOS inhibition andmay provide
a novel immunotherapeutic approach for improved radiation
therapeutic efficacy.
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